WO2008110491A3 - Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat - Google Patents
Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat Download PDFInfo
- Publication number
- WO2008110491A3 WO2008110491A3 PCT/EP2008/052682 EP2008052682W WO2008110491A3 WO 2008110491 A3 WO2008110491 A3 WO 2008110491A3 EP 2008052682 W EP2008052682 W EP 2008052682W WO 2008110491 A3 WO2008110491 A3 WO 2008110491A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- combination
- mtor pathway
- neoplastic diseases
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to compounds blocking or activating the mTOR pathway for use as a medicament in combination with rapamycin or a rapamycin-like compound and/or with metformin or a metformin-like compound and/or with thermal energy, for the treatment of neoplastic diseases, hyperproliferative conditions or other processes wherein mTOR is implicated. Experiments are described which demonstrate that mutational loss of Tsc2 or PTEN or down-regulating Tsc2 or PTEN by shRNA sensitizes cells for rapamycin and metformin and for thermal treatment, with synergies of these three forms of treatments. The invention further relates to a method to predict sensitivity of a tumor to the combination of mTOR pathway inhibition combined with application of thermal energy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103873 | 2007-03-09 | ||
| EP07103873.1 | 2007-03-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008110491A2 WO2008110491A2 (en) | 2008-09-18 |
| WO2008110491A3 true WO2008110491A3 (en) | 2008-12-11 |
Family
ID=39760141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/052682 Ceased WO2008110491A2 (en) | 2007-03-09 | 2008-03-05 | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008110491A2 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009112266A1 (en) * | 2008-03-12 | 2009-09-17 | Ludwig-Maximilians-Universität | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| WO2010022243A1 (en) * | 2008-08-20 | 2010-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemoprevention of head and neck squamous cell carcinomas |
| KR20120080579A (en) * | 2009-08-25 | 2012-07-17 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Use of metformin in cancer treatment and prevention |
| US20140235558A1 (en) * | 2010-06-15 | 2014-08-21 | Hanall Biopharma Co., Ltd. | Pharmaceutical composition having activity of anticancer |
| CA2824096A1 (en) * | 2011-01-11 | 2012-07-19 | Universitat Basel | Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| WO2013086002A1 (en) * | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| CN107109420A (en) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | Cancer Therapy Using CLL-1 Chimeric Antigen Receptor |
| CA2990107A1 (en) | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| KR101832892B1 (en) * | 2015-08-24 | 2018-02-27 | 가톨릭대학교 산학협력단 | Metformin-comprising compositions for preventing or treating mitochondrial diseases caused by immunosuppressive drugs and immune diseases |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| WO2019118407A1 (en) * | 2017-12-11 | 2019-06-20 | The Jackson Laboratory | Combination therapies for treatment of type ii diabetes |
| CN117887659A (en) * | 2018-05-01 | 2024-04-16 | 云南济慈再生医学研究院有限公司 | A method for promoting differentiation of target cells into neural cells |
| WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| CN112423843B (en) | 2018-06-15 | 2023-11-28 | 詹森药业有限公司 | Rapamycin analogues and uses thereof |
| WO2021113665A1 (en) | 2019-12-05 | 2021-06-10 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN114621338B (en) * | 2022-03-11 | 2022-11-11 | 中山大学 | mTOR inhibitor and application thereof |
-
2008
- 2008-03-05 WO PCT/EP2008/052682 patent/WO2008110491A2/en not_active Ceased
Non-Patent Citations (4)
| Title |
|---|
| DEGRAFFENRIED L A ET AL: "Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO OCT 2004, vol. 15, no. 10, October 2004 (2004-10-01), pages 1510 - 1516, XP002497599, ISSN: 0923-7534 * |
| IWAMARU A ET AL: "Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells", ONCOGENE, vol. 26, no. 13, 25 September 2006 (2006-09-25), pages 1840 - 1851, XP002497598, ISSN: 0950-9232 * |
| WUST P ET AL: "Hyperthermia in combined treatment of cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 3, no. 8, 1 August 2002 (2002-08-01), pages 487 - 497, XP004813895, ISSN: 1470-2045 * |
| ZAKIKHANI MAHVASH ET AL: "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells", CANCER RESEARCH, vol. 66, no. 21, November 2006 (2006-11-01), pages 10269 - 10273, XP002497600, ISSN: 0008-5472 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008110491A2 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008110491A3 (en) | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat | |
| WO2013059396A3 (en) | Treatment of cancer with tor kinase inhibitors | |
| HK1198579A1 (en) | Jak p13k/mtor combination therapy | |
| EA201490194A1 (en) | COMBINED THERAPY, INCLUDING CDK4 / 6 INHIBITOR AND PI3K INHIBITOR FOR USE IN CANCER TREATMENT | |
| WO2007100895A3 (en) | Cancer treatment with gamma-secretase inhibitors | |
| HK1221174A1 (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| WO2012068106A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| EA201201192A1 (en) | THIENOPYRIMIDINES CONTAINING A SUBSTITUTE ALKYL GROUP INTENDED FOR PHARMACEUTICAL COMPOSITIONS | |
| WO2012068096A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| WO2011133521A3 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
| BR112013002012A2 (en) | Methods and Compositions for Liver Cancer Therapy | |
| IL229786A (en) | Use of inhibitors for preparation of medicaments for treating ocular edema, neovascularization and related diseases | |
| BR112014003997A2 (en) | compound, method for inhibiting pak1 activity in a cell and patient, method for treating or improving the severity of cancer or a hyperproliferative disorder in a patient, use of the compound and composition | |
| WO2014066125A3 (en) | Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity | |
| HK1221144A1 (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| EA201491699A1 (en) | CANCER TREATMENT WITH TOR KINASE INHIBITORS | |
| MX2012010212A (en) | Thioxanthone-based autophagy inhibitor therapies to treat cancer. | |
| WO2013019945A3 (en) | Method for selection of chemotherapeutic agents for adenocarcinoma cancer | |
| PH12015500867B1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| WO2010037864A3 (en) | Inhibition of plgf to treat philadelphia chromosome positive leukemia | |
| IL227097B (en) | Combination comprising a proteasome inhibiting compound and an akt inhibitor, kit comprising same and use thereof for treating cancer | |
| WO2009045543A8 (en) | Treatment of conditions related to shock | |
| PH12012500911A1 (en) | Methods and compositions for treating solid tumors and other malignancies | |
| WO2009058908A3 (en) | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08717432 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08717432 Country of ref document: EP Kind code of ref document: A2 |